DSP Healthcare Fund - Direct Plan - Growth vs Nippon India Pharma Fund-Growth Plan-Bonus Option
Side-by-side comparison of NAV, returns, expense ratio and star rating.
TopFund Analysis
The DSP Healthcare Fund - Direct Plan - Growth appears stronger based on performance metrics, achieving a 1-year return of 18.92% and a 3-year CAGR of 20.63%, compared to Nippon India Pharma Fund-Growth Plan-Bonus Option's 1-year return of 11.76% and 3-year CAGR of 16.54%. However, investors should note that while DSP has a lower expense ratio of 0.75%, Nippon India has a significantly higher AUM of ₹9166 Cr, which may indicate greater market confidence. For investors deciding between these funds, DSP Healthcare Fund offers better returns but with a smaller asset base.
DSP Healthcare Fund - Direct Plan - Growth
DSP Mutual Fund
★★★★★
Equity · Sectoral Fund
Nippon India Pharma Fund-Growth Plan-Bonus Option
Nippon India Mutual Fund
★★★★★
Equity · Sectoral Fund
| Metric | DSP Healthcare Fund - ... | Nippon India Pharma Fu... |
|---|---|---|
| NAV | ₹52.14 | ₹582.42 |
| Star Rating | ★★★ | ★★ |
| Expense Ratio | 0.75% | 0.99% |
| AUM | ₹3,750 Cr | ₹9,166 Cr |
| 1M Return | +6.81% | +8.53% |
| 3M Return | +1.93% | +2.09% |
| 6M Return | +15.13% | +6.88% |
| 1Y Return | +18.92% | +11.76% |
| 3Y CAGR | +20.63% | +16.54% |
| 5Y CAGR | +17.0% | +13.76% |
| Risk Level | — | — |
| Fund Manager | Vinit Sambre | Sailesh Raj Bhan |